AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
iomeprol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| iodine-containing contrast media | 1463 | 78649-41-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| Vd (Volume of distribution) | 0.23 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 1.40 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 1 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 2.30 hours | Lombardo F, Berellini G, Obach RS |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,ACVRL1,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,NTRK2,PDK1,PDK2,PDK4,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,ZAP70 | 41 | |||
| kinase-selectivity-class | ALK,AURKA,AURKB,AURKC,AXL,BRAF,CAMK2A,CAMK2B,CAMK2D,CDK16,CDK2,CDK3,CDK4,CDK6,CDK7,CDK9,CLK2,CLK4,DDR1,DYRK1B,EIF2AK3,EPHB4,FLT3,FYN,GAK,GRK2,GSK3A,GSK3B,IRAK1,IRAK3,KDR,KIT,MAP2K6,MAP3K21,MAP3K7,MAP4K1,MAPK1,MAPK7,MARK4,PDK1,PIK3CB,PIK3CD,PIK3CG,PRKDC,SIK2,SIK3,STK10,STK17A,STK33,SYK,TEK,TGFBR1,TTK,TYRO3,UHMK1,ULK1,ULK2 | 57 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
None
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Rash maculo-papular | 458.92 | 39.50 | 112 | 1469 | 40821 | 90586045 |
| Eosinophilia | 288.29 | 39.50 | 72 | 1509 | 28461 | 90598405 |
| Drug reaction with eosinophilia and systemic symptoms | 277.98 | 39.50 | 76 | 1505 | 42682 | 90584184 |
| Acute generalised exanthematous pustulosis | 272.91 | 39.50 | 60 | 1521 | 13643 | 90613223 |
| Toxic skin eruption | 226.98 | 39.50 | 53 | 1528 | 15721 | 90611145 |
| Anaphylactic reaction | 61.13 | 39.50 | 30 | 1551 | 87494 | 90539372 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drug reaction with eosinophilia and systemic symptoms | 337.28 | 55.46 | 97 | 1081 | 41978 | 42578179 |
| Rash maculo-papular | 236.56 | 55.46 | 72 | 1106 | 37431 | 42582726 |
| Toxic skin eruption | 133.41 | 55.46 | 37 | 1141 | 13693 | 42606464 |
| Acute kidney injury | 117.09 | 55.46 | 89 | 1089 | 367248 | 42252909 |
| Acute generalised exanthematous pustulosis | 101.34 | 55.46 | 27 | 1151 | 8568 | 42611589 |
| Eosinophilia | 83.27 | 55.46 | 32 | 1146 | 32867 | 42587290 |
| Anaphylactic shock | 59.89 | 55.46 | 23 | 1155 | 23494 | 42596663 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Rash maculo-papular | 665.00 | 40.57 | 184 | 2652 | 74038 | 110512425 |
| Drug reaction with eosinophilia and systemic symptoms | 592.63 | 40.57 | 172 | 2664 | 81923 | 110504540 |
| Acute generalised exanthematous pustulosis | 349.48 | 40.57 | 86 | 2750 | 21578 | 110564885 |
| Toxic skin eruption | 348.49 | 40.57 | 90 | 2746 | 27425 | 110559038 |
| Eosinophilia | 341.20 | 40.57 | 104 | 2732 | 57832 | 110528631 |
| Acute kidney injury | 146.03 | 40.57 | 124 | 2712 | 635306 | 109951157 |
| Anaphylactic shock | 84.50 | 40.57 | 36 | 2800 | 51510 | 110534953 |
| Anaphylactic reaction | 75.71 | 40.57 | 43 | 2793 | 114257 | 110472206 |
| Rash morbilliform | 71.99 | 40.57 | 20 | 2816 | 7931 | 110578532 |
| Pruritus | 71.76 | 40.57 | 81 | 2755 | 581479 | 110004984 |
| Erythema | 60.65 | 40.57 | 54 | 2782 | 291393 | 110295070 |
| Symmetrical drug-related intertriginous and flexural exanthema | 59.72 | 40.57 | 13 | 2823 | 1884 | 110584579 |
| Dermatitis bullous | 56.42 | 40.57 | 20 | 2816 | 17509 | 110568954 |
| Contrast media reaction | 51.37 | 40.57 | 12 | 2824 | 2386 | 110584077 |
| Contrast media allergy | 42.25 | 40.57 | 11 | 2825 | 3412 | 110583051 |
| Suspected product contamination | 41.27 | 40.57 | 7 | 2829 | 270 | 110586193 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | V08AB10 | VARIOUS CONTRAST MEDIA X-RAY CONTRAST MEDIA, IODINATED Watersoluble, nephrotropic, low osmolar X-ray contrast media |
| FDA MoA | N0000010258 | X-Ray Contrast Activity |
| MeSH PA | D003287 | Contrast Media |
| MeSH PA | D064907 | Diagnostic Uses of Chemicals |
| FDA EPC | N0000180185 | Radiographic Contrast Agent |
| CHEBI has role | CHEBI:35703 | xenobiotic |
| CHEBI has role | CHEBI:37334 | diagnostic imaging agent |
| CHEBI has role | CHEBI:37338 | radioopaque medium |
| CHEBI has role | CHEBI:78298 | environmental contaminant |
Related Drugs by ATC class:
V08AB Watersoluble, nephrotropic, low osmolar X-ray contrast media 11 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 10.56 | acidic |
| pKa2 | 11.03 | acidic |
| pKa3 | 11.52 | acidic |
| pKa4 | 13.95 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 15GM IODINE/50ML (300MG IODINE/ML) | IOMERVU | BRACCO | N216016 | Nov. 27, 2024 | DISCN | SOLUTION | INTRA-ARTERIAL | Nov. 27, 2029 | NEW CHEMICAL ENTITY |
| 17.5GM IODINE/50ML (350MG IODINE/ML) | IOMERVU | BRACCO | N216016 | Nov. 27, 2024 | DISCN | SOLUTION | INTRA-ARTERIAL | Nov. 27, 2029 | NEW CHEMICAL ENTITY |
| 20GM IODINE/50ML (400MG IODINE/ML) | IOMERVU | BRACCO | N216016 | Nov. 27, 2024 | DISCN | SOLUTION | INTRA-ARTERIAL | Nov. 27, 2029 | NEW CHEMICAL ENTITY |
| 25GM IODINE/100ML (250MG IODINE/ML) | IOMERVU | BRACCO | N216016 | Nov. 27, 2024 | DISCN | SOLUTION | INTRA-ARTERIAL | Nov. 27, 2029 | NEW CHEMICAL ENTITY |
| 30GM IODINE/100ML (300MG IODINE/ML) | IOMERVU | BRACCO | N216016 | Nov. 27, 2024 | DISCN | SOLUTION | INTRA-ARTERIAL | Nov. 27, 2029 | NEW CHEMICAL ENTITY |
| 35GM IODINE/100ML (350MG IODINE/ML) | IOMERVU | BRACCO | N216016 | Nov. 27, 2024 | RX | SOLUTION | INTRA-ARTERIAL | Nov. 27, 2029 | NEW CHEMICAL ENTITY |
| 40GM IODINE/100ML (400MG IODINE/ML) | IOMERVU | BRACCO | N216016 | Nov. 27, 2024 | RX | SOLUTION | INTRA-ARTERIAL | Nov. 27, 2029 | NEW CHEMICAL ENTITY |
| 45GM IODINE/150ML (300MG IODINE/ML) | IOMERVU | BRACCO | N216016 | Nov. 27, 2024 | DISCN | SOLUTION | INTRA-ARTERIAL | Nov. 27, 2029 | NEW CHEMICAL ENTITY |
| 52.5GM IODINE/150ML (350MG IODINE/ML | IOMERVU | BRACCO | N216016 | Nov. 27, 2024 | DISCN | SOLUTION | INTRA-ARTERIAL | Nov. 27, 2029 | NEW CHEMICAL ENTITY |
| 60GM IODINE/150ML (400MG IODINE/ML) | IOMERVU | BRACCO | N216016 | Nov. 27, 2024 | DISCN | SOLUTION | INTRA-ARTERIAL | Nov. 27, 2029 | NEW CHEMICAL ENTITY |
| 60GM IODINE/200ML (300MG IODINE/ML) | IOMERVU | BRACCO | N216016 | Nov. 27, 2024 | DISCN | SOLUTION | INTRA-ARTERIAL | Nov. 27, 2029 | NEW CHEMICAL ENTITY |
| 70GM IODINE/200ML (350MG IODINE/ML) | IOMERVU | BRACCO | N216016 | Nov. 27, 2024 | RX | SOLUTION | INTRA-ARTERIAL | Nov. 27, 2029 | NEW CHEMICAL ENTITY |
| 80GM IODINE/200ML (400MG IODINE/ML) | IOMERVU | BRACCO | N216016 | Nov. 27, 2024 | RX | SOLUTION | INTRA-ARTERIAL | Nov. 27, 2029 | NEW CHEMICAL ENTITY |
| 15GM IODINE/50ML (300MG IODINE/ML) | IOMERVU | BRACCO | N216017 | Nov. 27, 2024 | DISCN | SOLUTION | INTRAVENOUS | Nov. 27, 2029 | NEW CHEMICAL ENTITY |
| 17.5GM IODINE/50ML (350MG IODINE/ML) | IOMERVU | BRACCO | N216017 | Nov. 27, 2024 | DISCN | SOLUTION | INTRAVENOUS | Nov. 27, 2029 | NEW CHEMICAL ENTITY |
| 20GM IODINE/50ML (400MG IODINE/ML) | IOMERVU | BRACCO | N216017 | Nov. 27, 2024 | DISCN | SOLUTION | INTRAVENOUS | Nov. 27, 2029 | NEW CHEMICAL ENTITY |
| 25GM IODINE/100ML (250MG IODINE/ML) | IOMERVU | BRACCO | N216017 | Nov. 27, 2024 | DISCN | SOLUTION | INTRAVENOUS | Nov. 27, 2029 | NEW CHEMICAL ENTITY |
| 30GM IODINE/100ML (300MG IODINE/ML) | IOMERVU | BRACCO | N216017 | Nov. 27, 2024 | DISCN | SOLUTION | INTRAVENOUS | Nov. 27, 2029 | NEW CHEMICAL ENTITY |
| 35GM IODINE/100ML (350MG IODINE/ML) | IOMERVU | BRACCO | N216017 | Nov. 27, 2024 | RX | SOLUTION | INTRAVENOUS | Nov. 27, 2029 | NEW CHEMICAL ENTITY |
| 40GM IODINE/100ML (400MG IODINE/ML) | IOMERVU | BRACCO | N216017 | Nov. 27, 2024 | RX | SOLUTION | INTRAVENOUS | Nov. 27, 2029 | NEW CHEMICAL ENTITY |
| 45GM IODINE/150ML (300MG IODINE/ML) | IOMERVU | BRACCO | N216017 | Nov. 27, 2024 | DISCN | SOLUTION | INTRAVENOUS | Nov. 27, 2029 | NEW CHEMICAL ENTITY |
| 52.5GM IODINE/150ML (350MG IODINE/ML) | IOMERVU | BRACCO | N216017 | Nov. 27, 2024 | DISCN | SOLUTION | INTRAVENOUS | Nov. 27, 2029 | NEW CHEMICAL ENTITY |
| 60GM IODINE/150ML (400MG IODINE/ML) | IOMERVU | BRACCO | N216017 | Nov. 27, 2024 | DISCN | SOLUTION | INTRAVENOUS | Nov. 27, 2029 | NEW CHEMICAL ENTITY |
| 60GM IODINE/200ML (300MG IODINE/ML) | IOMERVU | BRACCO | N216017 | Nov. 27, 2024 | DISCN | SOLUTION | INTRAVENOUS | Nov. 27, 2029 | NEW CHEMICAL ENTITY |
| 70GM IODINE/200ML (350MG IODINE/ML) | IOMERVU | BRACCO | N216017 | Nov. 27, 2024 | RX | SOLUTION | INTRAVENOUS | Nov. 27, 2029 | NEW CHEMICAL ENTITY |
| 80GM IODINE/200ML (400MG IODINE/ML) | IOMERVU | BRACCO | N216017 | Nov. 27, 2024 | RX | SOLUTION | INTRAVENOUS | Nov. 27, 2029 | NEW CHEMICAL ENTITY |
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| D01719 | KEGG_DRUG |
| C0063810 | UMLSCUI |
| CHEBI:31710 | CHEBI |
| CHEMBL2107214 | ChEMBL_ID |
| DB11705 | DRUGBANK_ID |
| C057937 | MESH_SUPPLEMENTAL_RECORD_UI |
| 5859 | INN_ID |
| 17E17JBP8L | UNII |
| 3731 | PUBCHEM_CID |
| 2606484 | RXNORM |
| 19468 | MMSL |
| 38161 | MMSL |
| d05472 | MMSL |
| 006219 | NDDF |
| 356671000 | SNOMEDCT_US |
| 395753004 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| IOMERVU | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0270-7017 | INJECTION, SOLUTION | 714 mg | INTRA-ARTERIAL | NDA | 25 sections |
| IOMERVU | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0270-7018 | INJECTION, SOLUTION | 816 mg | INTRA-ARTERIAL | NDA | 25 sections |
| Iomeron | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0270-7250 | INJECTION, SOLUTION | 510 mg | INTRAVASCULAR | Unapproved drug for use in drug shortage | 3 sections |
| Iomeron | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0270-7300 | INJECTION, SOLUTION | 612 mg | INTRAVASCULAR | Unapproved drug for use in drug shortage | 3 sections |
| Iomeron | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0270-7350 | INJECTION, SOLUTION | 714 mg | INTRAVASCULAR | Unapproved drug for use in drug shortage | 3 sections |
| Iomeron | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0270-7400 | INJECTION, SOLUTION | 816 mg | INTRAVASCULAR | Unapproved drug for use in drug shortage | 3 sections |
| Iomeron | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0270-9300 | INJECTION, SOLUTION | 612 mg | INTRAVASCULAR | Unapproved drug for use in drug shortage | 3 sections |
| Iomeron | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0270-9350 | INJECTION, SOLUTION | 714 mg | INTRAVASCULAR | Unapproved drug for use in drug shortage | 3 sections |
| Iomeron | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0270-9400 | INJECTION, SOLUTION | 816 mg | INTRAVASCULAR | Unapproved drug for use in drug shortage | 3 sections |
| Iomeron | HUMAN PRESCRIPTION DRUG LABEL | 1 | 76381-725 | INJECTION, SOLUTION | 510 mg | INTRAVASCULAR | Unapproved drug for use in drug shortage | 3 sections |
| Iomeron | HUMAN PRESCRIPTION DRUG LABEL | 1 | 76381-730 | INJECTION, SOLUTION | 612 mg | INTRAVASCULAR | Unapproved drug for use in drug shortage | 3 sections |
| Iomeron | HUMAN PRESCRIPTION DRUG LABEL | 1 | 76381-735 | INJECTION, SOLUTION | 714 mg | INTRAVASCULAR | Unapproved drug for use in drug shortage | 3 sections |
| Iomeron | HUMAN PRESCRIPTION DRUG LABEL | 1 | 76381-740 | INJECTION, SOLUTION | 816 mg | INTRAVASCULAR | Unapproved drug for use in drug shortage | 3 sections |
| Iomeron | HUMAN PRESCRIPTION DRUG LABEL | 1 | 76381-930 | INJECTION, SOLUTION | 612 mg | INTRAVASCULAR | Unapproved drug for use in drug shortage | 3 sections |
| Iomeron | HUMAN PRESCRIPTION DRUG LABEL | 1 | 76381-935 | INJECTION, SOLUTION | 714 mg | INTRAVASCULAR | Unapproved drug for use in drug shortage | 3 sections |
| Iomeron | HUMAN PRESCRIPTION DRUG LABEL | 1 | 76381-940 | INJECTION, SOLUTION | 816 mg | INTRAVASCULAR | Unapproved drug for use in drug shortage | 3 sections |